(PharmaNewsWire.Com, August 12, 2021 ) Non-Invasive Prenatal Testing Market size is estimated to reach $9.8 billion by 2026, growing at a CAGR of 13.1% during the forecast period 2021-2026. Prenatal testing is a procedure of determining the risk of whether the fetus of the mother will be born with any genetic abnormalities. This method also analyzes fragments of Deoxyribonucleic acid (DNA) that are circulating in pregnant blood. This non-invasive prenatal testing has grown out of a desire to avoid direct contact with the fetus. The rise in the adoption of cell-free DNA screening for predicting the risk of genetic conditions, growing adoption of ultrasound detection methods in hospitals, increase in the risk of chromosomal abnormalities with rising maternal age, and growing demand for chorionic villus sampling and amniocentesis in diagnostic laboratories are the factors that are set to drive the growth of the Non-Invasive Prenatal Testing Market for the period 2021-2026.
The Non-Invasive Prenatal Testing Market based on the Method can be further segmented into Ultrasound Detection, Biochemical Screening Test, Cell-free DNA Screening in Maternal Plasma Test, and Fetal Cell in Maternal Blood Test. The Cell-free DNA Screening in Maternal Plasma Test segment held the largest share in 2020 and is also estimated to be the fastest growing segment with a CAGR of 14.7% over the period 2021-2026.
This growth is owing to the factors such as the rise in the company initiatives to develop new products and growing research studies to further advance the use of tests offered. The rise in the adoption of Cell-free DNA Screening for predicting the risk of genetic conditions is driving the growth of the Non-Invasive Prenatal Testing Market. The Ultrasound Detection segment held the second largest share in 2020 owing to the factors such as the growing demand for non-invasive and safe methods for both mother and unborn baby and the rise in the adoption of ultrasound detection as complementary to Cell-free DNA screening.
Non-Invasive Prenatal Testing Market Segment Analysis-By End User
The Non-Invasive Prenatal Testing Market based on the End User can be further segmented into Diagnostic Laboratories, Hospitals, and Others. The Diagnostic Laboratories segment held the largest share in 2020 and is also estimated to be the fastest growing segment with a CAGR of 14.3% over the period 2021-2026. This growth is owing to the factors such as increase in the initiatives by diagnostic laboratories to provide effective prenatal tests and growing incidences of chromosomal abnormalities.
The growing demand for chorionic villus sampling and amniocentesis in diagnostic laboratories is driving the growth of the Non-Invasive Prenatal Testing Market. The Hospitals segment held the second largest share in 2020 owing to the factors such as the growing adoption of ultrasound detection methods in hospitals in developed nations and the increase in the investment by the key players to launch advanced equipment in hospitals.
North America held the largest share with 31% of the overall market in 2020. The growth in this segment is owing to the factors such as rise in the demand for chorionic villus sampling and amniocentesis in diagnostic laboratories and increase in the risk of chromosomal abnormalities with rising maternal age. The rise in the adoption of ultrasound detection methods in developed nations is driving the growth of the Non-Invasive Prenatal Testing Market.
Asia-Pacific segment is estimated to be the fastest growing segment over the period 2021-2026. The growth in this segment is owing to the factors such as the growing adoption of Cell-free DNA Screening for predicting the risk of genetic conditions and the increase in the initiatives by governments and diagnostic laboratories to provide effective prenatal tests.
The Cell-free DNA screening in maternal plasma tests has a lower false rate and a higher detection rate than other screening methods. Cell-free DNA screening test has the ability to determine whether a mother has a chance of having a fetus with trisomy syndrome. The rise in the adoption of Cell-free DNA Screening in predicting the risk of genetic conditions and growing research studies are further propelling the growth of the Non-Invasive Prenatal Testing Market.
Increase in the Risk of Chromosomal Abnormalities with Rising Maternal Age
The maternal age has been shifted owing to various social and economic factors and has resulted in an increase in the prevalence of chromosomal abnormalities. There is a rapid increase in the demand for developing advanced diagnostic procedures for early screening to detect genetic abnormalities resulted from the improper division of chromosomes, which is one of the major factors driving the growth of the Non-Invasive Prenatal Testing Market.
Non-Invasive Prenatal Testing Market Challenges
High Cost of Non-Invasive Prenatal Testing
The key players are focusing on developing advanced screening technologies that are effective and accurate in the early detection of genetic disorders owing to the rising chromosomal abnormalities. However, the high cost of Non-Invasive Prenatal Testing is one of the major factors that is estimated to reduce the growth of the Non-Invasive Prenatal Testing Market.
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Non-Invasive Prenatal Testing Market. Key companies of this market are Agilent Technologies Inc, F Hoffman-La Roche Ltd, Illumina Inc, Koninklijke Philip N.V., Thermo Fisher Scientific Inc, Perkinelmer, Inc, Qiagen N.V., Natera Inc, Progenity Inc, and CooperSurgical Inc among others.
Partnerships/Product Launches:
In June 2020, Koninklijke Philip N.V. has launched noninvasive prenatal testing device, Fetal and Maternal Pod and Patch to allow for continuous monitoring of maternal heart rate and to provide multiple benefits to expectant mothers, such as mobility, and flexibility.
In June 2019, Thermo Fisher Scientific has entered into a partnership with NX Prenatal to detect and manage pregnancy-related complications using novel non-invasive prenatal testing methods and to develop mass spectrometry (MS)-based proteomics assays for assessing the risk of adverse outcomes.
In April 2019, Progenity Inc has launched Resura, which is a custom-designed and noninvasive prenatal test for monogenic diseases to broaden parents’ prenatal testing options and to include a noninvasive test tailored to the family’s risk for a specific disease.
Key Takeaways
Geographically, North America Non-Invasive Prenatal Testing Market accounted for the highest revenue share in 2020 and it is poised to dominate over the period 2021-2026 owing to the growing demand for chorionic villus sampling and amniocentesis in diagnostic laboratories.
The rise in the adoption of cell-free DNA screening for predicting the risk of genetic conditions is driving the Cell-free DNA Screening in Maternal Plasma Test segment. However, the high cost of non-invasive prenatal testing is one of the major factors that is said to reduce the growth of the Non-Invasive Prenatal Testing Market.
Detailed analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Non-Invasive Prenatal Testing Market report.
For more Lifesciences and Healthcare Market reports, please click here
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
